Aortic insufficiency; Non-pharmaceutical and pharmaceutical treatment of HTN Flashcards
General approach to HTN treatment and management
- Lifestyle changes for management of ALL HTN patients
- Identify indications for pharmacological treatment
- Select first line treatments based on individual patient characteristics and comorbidities
- Titrate treatment to reach target BP [Target BP for 65 and younger < 130/80 mmHg; Target BP for 65 and older < 140/90 mmHg]. Always ensure individual approach over general approach
- Regular follow-ups to ensure adherance to regime, changes/resistance in BP control or development of unwanted side effects
Non-pharmacological treatments of HTN [which type of patients, methods]
Eligible patients:
- ALL patients with HTN, especially those with Elevated or Stage 1 HTN [ < 150mmHg and < 90mmHg] with < 10% 10 year ASCVD risk
- Trialed for 3-6 months before considering drug based management
- Changes in lifestyle in addition to pharmacological therapy shows the most potent effects
Management plans: Weight loss most effective measure
DIET
- DASH diet [rich in fruits, vegetables, whole grains; avoids trans and saturated fats]: Potential to reduce upto 11 mmHg SBP
- Decrease dietary Sodium [< 1500mg daily intake]: Potential to reduce upto 5-6 mmHg SBP
- Increase dietary Potassium [by increasing fruit and vegetable intake]
- Decrease alcohol intake
EXERCISE
- Aerobic [90-150 min/week]: Potential to reduce upto 5-8 mmHg SBP
- Dynamic resistance/weight training
- Isometric resistance
Smoking cessation alone significantly reduces CVD risk in the future
Psychosocial factors or other social determinants of health must be addressed along with lifestyle changes to ensure adherence and effectiveness
Increased Potassium intake NOT RECOMMENDED for CKD patients
Indications for Antihypertensive Treatment
Controversial and vary according to age
ALL adults with SBP > 140mmHg OR DBP > 90 mmHg
Adults with SBP >130 mmHg or DBP > 80mmHg AND one of the following:
- Clinical ASCVD [IHD, PAD, previous stroke] or CHF
- 10-year ASCVD risk > 10% [for ages 65 and older including DM]
Based on 2017 ACC/AHA guidelines
How to consider initial medication for HTN
Patients Initial BP:
- SBP 130-139mmHg or DBP 80-89mmHg: Consider monotherapy with first-line drugs
- SBP > 140mmHg or DBP > 90mmHg AND average blood pressure > 20/10mmHg above target: Consider combination therapy of first-line drugs [prescribe single, combination pills when possible to ensure greater patient adherence]
Additional Factors:
- Consider major comorbidities and include Second-line and changes in drug choice based on response
- Adverse effects not tolerable to patients, change drug choice
- Always revisit treatment plan and individualize approach to treatment
First-line anti-hypertensive drug of choice
ACE inhibitors: [-pril class drugs] Nephroprotective
- Lisinopril
- Enalapril
- Captopril
Angiotensin Receptor Blockers [ARBS]: [-artan class drugs] Nephroprotective
- Losartan
- Valsartan
Thiazide DIuretics: [isolated Systolic HTN; Black american patients initial choice]
- Chlorthalidone
- Hydrochlorothiazide
Dihydropyridine CCB: [can be combined with all other first line choices; indications same as thiazide diuretics]
- Amlodipine
- Nifedipine
Non-dihydropyridine CCB: [less commonly used]
- Diltiazem
- Verapamil
First line drugs for Primary HTN are Thiazide Diuretics, ACEIs, ARBs and dihydropyridine CCBs
Commonly used combination therapy drugs for HTN
ACEIs/ARBs + dihydropyridine CCBs/Thiazide diuretics
DO NOT prescribe ACEIs and ARBs together or in combination with Direct Renin Inhibitors, as this increases risk of Hyperkalemia and Renal dysfuntion
Common comorbidities with HTN
- History of stroke/TIA
- Stable Ischemic Heart Disease
- CKD
- Diabetes
- CHF
- Asthma
- Osteoporosis
- Gout
- Migraine
In Osteoporosis: Thiazide diuretics [helps prevent calcium loss]
In Gout: Thiazide diuretics avoided [increases uric acid levels]; ARBs, ACEIs and CCBs used
In Migraine: Beta blockers/CCBs used
Treatment options for HTN + History of stroke/TIA
- Monotherapy: ACEIs/ARBs/Thiazide diuretic
- Comb therapy: Thiazide + ACEIs/ARBs
- Goal: BP < 130/80 mmHg in most patients
Treatment options for HTN + Stable IHD
- Initial: ACEIs/ARBs + Beta blockers
- Add on for angina patients: dihydropyridine CCBs
- Add on for non-angina patients: dihydropyridine CCBs/Thiazides/Aldosterone antagonists
- Goal: BP < 130/80 mmHg
Treatment options for HTN + CKD
- Initial patients with microalbuminemia + diabetes/over proteinuria: ACEIs/ARBs
- Initial patients with microalbuminemia without diabetes: ACEIs/ARBs
- Combination: ACEIs/ARBs + CCBs +/- Thiazide diuretic
- Goal: SBP < 120mmHg [if tolerated]
CKD recommendation based on 2021 KDIGO CKD guidelines
Treatment options for HTN + Diabetes
- Initial patients with microalbuminemia or overt proteinuria: ACEIs/ARBs [protective against diabetic nephropathy]
- Inital patients without microalbuminemia: any first line agent
- Goal: BP < 130/80 mmHg
Treatment options for HTN + CHF
HFrEF:
- Beta blockers [carvediol/metoprolol succinate/bisprolol] use catiously in decompensated CHF, contraindication in cardiogenic shock
- Diuretics [including aldosterone antagonists[
- ACEIs/ARBs
- Angiotensin receptor-neprilysin inhibitor
- Goal: BP < 130/80 mmHg
HFpEF:
- Diuretics for current volume overload
- ACEIs/ARBs + Beta blockers for no current volume overload
- Avoid nitrates
- Goal: SBP < 130 mmHg
DO NOT use dihydropyridine CCBs in HFrRF for myocardial depressing eff
Common Second-line antihypertensive drug choices
Beta Blockers [first line only in IHD, HF, AFib, Thoracic aorta disease, Thyrotoxicosis, Migraine, Essential tremor comorbid patients]
Combined alpha and beta:
- Carvediol
- Labetalol
Noncardioselective:
- Nadolol
- Propranolol
Cardioselective:
- Atenolol
- Bisoprolol
- Metoprolol succinate
Loop Diuretics: [preferred diuretic in patients with symptomatic HF and CKD, if GFR < 30mL/min]
- Furosemide
- Torsemide
Potassium-sparing Diuretics
Aldosterone Antagonists: [in HTN due to primary hyperaldosteronism]
- Spironolactone
- Eplerenone
- Finerenone [nonsteroidal]
Epithelial Sodium Channel Blockers [not very effective; consider add on for hypokalemia receiving thiazide diuretics]
- Amiloride
- Triamterene
Direct Renin Inhibitors: [rarely used]
- Aliskiren
Alpha-1 Blockers: [Pheochromocytoma induced HTN; adjunct in BPH patients]
- Prazosin
- Doxazosin
Alpha-2 Agonists: [rarely used]
- Clonidine
- Methyldopa
Direct Arterolar Vasodilators:
- Hydralazine [drug of choice in pregnant patients]
- Minoxidil [given with loop diuretics]
What is Aortic Insufficiency?
Aortic Insufficiency aka Aortic Regurgitation is a condition where the Aortic valves do not close completely at the end of systole, allowing blood to flow back into the Left Ventricle [aka regurgitation] causing changes in the heart ex. LV hypertrophy [to match SV from high end-diastolic volume in LV], Congestion in left side of heart and pulmonary circulation, LHF, etc
AR is basically precursor to Heart Failure
Etiologies of Aortic Insufficiency
Divided into Acute and Chronic causes
Acute:
- Infective Endocarditis [most common valvular cause]
- Aortic Dissection [most common non-valvular cause]
- Chest Trauma
- Iatrogenic [post TAVR or percutaneous ballon dilation of aorta]
Chronic:
Primary Valvular causes
- Congeital Bicuspid Aortic Valve
- Calcified Aortic valves [~ 76% of AS patients also have AR]
- Rheumatic Heart disease [more common in lower-income countries]
Aortic dilatation causes
- Connective Tissue disorders [Marfan syndrome, Ehlers-Danlos syndrome]
- Chronic HTN
- Aortic aneurysm
- Aortitis of any etiology [especially tertiary syphilis]
Aortic Dilatation causing AR does not always or necessarily involve the Aortic Valves themselves in the pathophysiology, however they do lead to AR at some point in some patients